Payment overview · 2025
General Payments
$117.89
7 reported records · 5 companies
Healthcare provider profile · identity verified
Ronald L. Gemma, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · INDIANAPOLIS, IN · NPI 1508919077
Verified facts
What the public records show
CMS Open Payments records show Ronald L. Gemma, D.O. received $117.89 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.92 | 35.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.12 | 18.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.15 | 16.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.40 | 14.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.30 | 14.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.89 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.76 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 20 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 532 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 114 |
| Losartan Potassium | Losartan Potassium | 313 | 89 |
| Gabapentin | Gabapentin | 239 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 62 |
| Trazodone Hcl | Trazodone Hcl | 178 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 44 |
| Lisinopril | Lisinopril | 138 | 39 |
| Mounjaro | Tirzepatide | 129 | 24 |
| Ozempic | Semaglutide | 121 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 29 |
| Tramadol Hcl | Tramadol Hcl | 114 | 22 |
| Metformin Hcl Er | Metformin Hcl | 113 | 33 |
| Metformin Hcl | Metformin Hcl | 110 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 32 |
| Omeprazole | Omeprazole | 98 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 31 |
| Jardiance | Empagliflozin | 84 | 20 |
| Potassium Chloride | Potassium Chloride | 83 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 17 |
| Carvedilol | Carvedilol | 79 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 22 |
| Eliquis | Apixaban | 77 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 21 |
| Montelukast Sodium | Montelukast Sodium | 75 | 20 |
| Furosemide | Furosemide | 73 | 21 |
| Pregabalin | Pregabalin | 71 | 19 |
| Glimepiride | Glimepiride | 68 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 16 |
| Spironolactone | Spironolactone | 64 | 16 |
| Meloxicam | Meloxicam | 61 | 14 |
| Famotidine | Famotidine | 60 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 17 |
| Bupropion Xl | Bupropion Hcl | 56 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 19 |
| Atenolol | Atenolol | 49 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 17 |
| Finasteride | Finasteride | 47 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Sertraline Hcl | Sertraline Hcl | 46 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 11 |
| Chlorthalidone | Chlorthalidone | 41 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 12 |
| Allopurinol | Allopurinol | 38 | 13 |
| Ezetimibe | Ezetimibe | 38 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 11 |
| Diazepam | Diazepam | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Telmisartan | Telmisartan | 37 | suppressed |
| Acyclovir | Acyclovir | 36 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 13 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 20 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 17 | 17 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Benicar | Olmesartan Medoxomil | 11 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.89 · 7 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, GVOKE HYPOPEN, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, Veozah, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error